Loading...
Powered By
4 items
2025-05-15
Shirohato Co., Ltd. announced that they will report Q1, 2026 results on Jul 11, 2025
2025-04-11
Shirohato Co., Ltd., Annual General Meeting, May 29, 2025.
2025-02-28
Shirohato Co., Ltd. announced that they will report fiscal year 2025 results on Apr 11, 2025
2024-11-18
C.I. Medical Co.,Ltd. (TSE:3540) proposed to acquire an additional 17.10% stake in Shirohato Co., Ltd. (TSE:3192) for approximately ¥320 million on November 15, 2024. A cash consideration valued at ¥280 per share will be paid by C.I. Medical Co.,Ltd. As part of consideration, an undisclosed value is paid towards common equity of Shirohato Co., Ltd. Upon completion, C.I. Medical Co.,Ltd. will own 50.30% stake in Shirohato Co., Ltd. The transaction is subject to minimum tender. SBI Securities Co. Ltd. acted as financial advisor for C.I. Medical Co.,Ltd. TMI Associates acted as legal advisor for C.I. Medical Co.,Ltd. Kitahama Partners acted as legal advisor for Shirohato Co., Ltd. Tender offer agent is SBI Securities Co., Ltd.
2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | 2023Q3 | |
|---|---|---|---|---|---|---|---|
Total Revenues | 6,274 | 6,107 | 6,139 | 6,213 | 6,372 | 6,339 | 6,199 |
Pretax Income Excl.Unusual Items | 3 | -27 | -40 | -58 | -56 | -57 | -63 |
Total Assets | 5,959 | 6,328 | 5,849 | 5,944 | 5,760 | 6,305 | 5,978 |
Total Liabilities | 3,754 | 4,280 | 3,802 | 3,903 | 3,678 | 4,196 | 3,854 |
Cash & Cash Equivalents | 554 | 344 | 321 | 95 | 193 | 266 | 275 |
Total Common Equity | 2,205 | 2,048 | 2,047 | 2,041 | 2,082 | 2,109 | 2,124 |
Book Value Per Share (BVPS) | 331.28 | 307.69 | 307.54 | 306.64 | 312.8 | 316.86 | 319.11 |
Net Change in Cash | 361 | 45 | -499 | -440 | |||
Capital Expenditure | -2 | -4 | -4 | -3 |
Shirohato revealed its financial results for the first quarter of 2025 on May 30, 2025, having revenues of 1.81B yen and net income of 156M yen, representing a revenue increase of 10.2%, with a transition from a loss per share in the same quarter last year to a profit per share in the current quarter.
Moreover, the EBITDA margin witnessed a sharp rise from 3.7% in the same quarter last year to 5.1%. This increase is usually indicative of the company raising prices or implementing optimization techniques in its business sectors, leading to higher EBITDA margins and, consequently, improving the stock's performance in the future. and it trades at 15.1x times current year's earnings, which is higher than the sector average (P/E 13x).